UniDoc Health Lists on Frankfurt Exchange and Introduces Board of Directors

Telehealth Team Assembles to Launch Rapid Development Program

VANCOUVER, BC, — (December 21, 2021) – UniDoc Health Corp. (CSE: UDOC) (FRA: L7T) (“UniDoc,” or the “Company”), an innovator in the telehealth sector, is pleased to advise of its public listing on the Frankfurt Stock Exchange and further introduces its executive leadership and Board Directors as an integral part of its strategic plan. More information is available on the Company website at www.unidoctor.com.

Frankfurt Stock Exchange Listing

UniDoc Health advises today that the company’s common shares are now listed on the Frankfurt Stock Exchange under the ticker symbol “L7T” or identified as WKN A3C87U. The Frankfurt Stock Exchange (Börse Frankfurt – FRA), operated by Deutsche Borse AG, is one of the world’s largest trading centres for securities and the largest of the eight stock exchanges in Germany. The UniDoc Health Frankfurt listing is expected to facilitate the process of trading in its shares by investors in Europe and internationally. The company’s shares continue to be listed on the Canadian Securities Exchange (CSE) under the symbol UDOC.

UniDoc is a virtual health/telemedicine solutions company which is developing its proprietary Virtual Care Solutions Model, a customizable, and comprehensive telehealth solution that integrates a range of physical products, web-based services, and analytical tools, along with access to the Company’s developing network of Healthcare Providers, pharmacies, and hospitals.

The Company aims to rapidly advance product development and commercialization and is pleased today to present its Board of Directors and key leadership as follows:

Antonio Baldassarre CEO, President and Director

Mr. Baldassarre has held senior management and director positions of new business start-ups and established multinational organizations with over 30 years of experience in the Security, Information Technology and Communications industries. With leadership skills in management of international operations, shareholder exit strategies, and overall business development, he has utilized a wide range of strategic programs to maximize organic growth into specific industry segments through OEM, alliances, and direct multi-level distribution channels. Mr Baldassarre brings extensive experience in the planning and execution of all aspects of corporate management from Operations, P&L oversight, product distribution, product promotions, sales and development activities and initiatives. He is also the President of LRG Security Canada Inc. and LRG Security Europe.

Franco Staino, Board Chair

Mr. Staino is a business professional with over 40 years experience in the pharmaceutical industry. He brings significant experience in drug safety, traceability and anti-counterfeiting measures and has designed and implemented programs for the Italian National Health Service, the Ministry of Health and the Polygraphic Institute and State Mint. He currently holds multiple positions including as control representative of Carlucci a leading company engaged in the production of self-adhesive labels for consumer goods specialized for the pharmaceutical sector, and as President of the Board of Directors of Topharmacia, a management company for pharmacies throughout Italy.

Nina Yii, CFO and Corporate Secretary

Ms. Yii is a Chartered Professional Accountant (CPA), with over ten years of accounting, regulatory, and financial reporting experience. Ms. Yii provides accounting and financial reporting services and accounting services to public companies in various industries both in the United States and Canada.

Sina Pirooz, Director

Mr. Pirooz is a registered and practicing pharmacist and has been a professional member of the College of Pharmacists of British Columbia since 2003, with over 20 years of pharmaceuticals and pharmacy management experience. As the owner of a compounding pharmacy, Mr. Pirooz has been dispensing pharmaceuticals for over 18 years and provides pharmacist and pharmacy management services to many of Canada’s largest pharmacy chains and drug stores. Mr. Pirooz is also the CEO and a director of Genix Pharmaceuticals Corporation, a company listed for trading on the TSXV.

Matt Chatterton, Director

Mr. Chatterton brings over 15 years of experience is development and execution of complex projects. His expertise includes project management, facility management, logistics, supply side processes and procedures at several operations in Canada and internationally. He has been involved in the public markets for the last three-years managing IPO processes and transitioning businesses to post listing operations. Mr. Chatterton is a Professional Engineer and graduate of Canada’s Queens University with a Master’s degree in Chemical Process Engineering (2003).

Austin Thornberry, Director

Mr. Thornberry is a seasoned finance professional with a background in advising startup companies in the venture capital market. He brings extensive experience working with high-growth companies across numerous industries through his past work in the Technology & Innovation banking group at the Bank of Montreal and in the financial services arm of Ernst & Young advising on multiple capital markets transactions. He obtained his Bachelor of Commerce at McGill University and has held the CPA, CA, designation since 2019.

Marketing and Investor Relations Agreements

In related news, the Company also announces it has signed an agreement with Promethean Marketing to provide investor awareness and digital marketing services. The agreed upon term commences on December 14, 2021 and continue on a month-to-month basis. As consideration for the services, the Company has made payments totalling US$250,000. The Company also announces it has signed an agreement with Clarkham Capital to provide investor relations and digital marketing services. The agreed upon term shall last three months, commencing December 15, 2021. As consideration for the services the Company has made payments totalling €75,000. The Company also announces it has signed an agreement with Gina Capital to provide investor relations and digital marketing services. The agreed upon term shall last three months, commencing December 15, 2021. As consideration for the services the Company has made payments totalling €75,000.\

UniDoc encourages interest, active engagement, thoughtful questions and business inquiries. We invite anyone interested in our story to visit our website at www.unidoctor.com and signup to receive our latest news regarding updates on our activities, events, and progress.

As part of the Company’s disclosure obligations as a public issuer, ongoing financial and material filings can be found under the Company’s profile on the System for Electronic Document Analysis and Retrieval (SEDAR) at www.sedar.com.

About UniDoc Health Corp. (CSE: UDOC) (FRA: L7T)

UniDoc is developing a telehealth solution which is being designed as a self-contained remote virtual clinic within a private kiosk for patients to undergo full consultations as if they were present in a physician’s office. Telehealth opens the doors to a large segment of the population challenged by access, experience or understanding of online computer technology. It is the Company’s belief that physical accessibility is the key to its business proposition. UniDoc is dedicated to unlocking shareholder value by delivering an excellent product and sophisticated commercial network within an expedited timeframe. Find out more at: https://unidoctor.com and connect with our social media on Facebook, Twitter or Instagram.

For further information, please contact

UniDoc Investor Relations
Tel: +1 778.383.6731
Email: info@unidoctor.com

Austin Thornberry, Director
Tel: +1 647.463.8689
Email: austin@unidoctor.com

Media Inquiries
media@unidoctor.com

Forward Looking Statement

This news release contains statements and information that, to the extent that they are not historical fact, may constitute “forward-looking information” within the meaning of applicable securities legislation. Forward-looking information may include financial and other projections, as well as statements regarding future plans, objectives, or economic performance, or the assumption underlying any of the foregoing. In some cases, forward-looking statements can be identified by terms such as “may”, “would”, “could”, “will”, “likely”, “except”, “anticipate”, “believe”, “intend”, “plan”, “forecast”, “project”, “estimate”, “outlook”, or the negative thereof or other similar expressions concerning matters that are not historical facts. Examples of such statements include, but are not limited to, statements with respect to the anticipated features of the Virtual Care Solutions Model.

Forward-looking information is based on the assumptions, estimates, analysis, and opinions of management made in light of its experience and its perception of trends, current conditions and expected developments, as well as other factors that management believes to be relevant and reasonable in the circumstances at the date that such statements are made, but which may prove to be incorrect. The material factors and assumptions used to develop the forward-looking information contained in this news release include, but are not limited to, key personnel and qualified employees continuing their involvement with the Company; the Company’s ability to secure additional financing on reasonable terms; the competitive conditions of the industries in which the Company operates; and laws and any amendments thereto applicable to the Company

Forward-looking information involves known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company to differ materially from any future results, performance or achievements expressed or implied by the forward-looking information, including, without limitation,  risks relating to the future business plans of the Company; risks that the Company will not be able to retain its key personnel; risks that the Company will not be able to secure financing on reasonable terms or at all, as well as all of the other risks as described in the Company’s  final prospectus dated December 2, 2021 under the heading “Risks Factors.” Accordingly, readers should not place undue reliance on any such forward-looking information. Further, any forward-looking information speaks only as of the date on which such statement is made. New factors emerge from time to time, and it is not possible for the Company’s management to predict all such factors and to assess in advance the impact of each such factor on the Company’s business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking information. The Company does not undertake any obligation to update any forward-looking information to reflect information or events after the date on which it is made or to reflect the occurrence of unanticipated events, except as required by law, including securities laws.

The CSE does not accept responsibility for the adequacy or accuracy of this release.

Sign Up For News Alerts

Enter your details below and we will add you to our News Alerts list.

Consent(Required)

Sina Pirooz

Director

Mr. Pirooz is a registered and practicing pharmacist, and has been a professional member of the College of Pharmacists of British Columbia since 2003, with over 20 years of pharmaceuticals and pharmacy management experience. As owner of a compounding pharmacy, Mr. Pirooz has been dispensing pharmaceuticals for over 18 years and provides pharmacist and pharmacy management services to many of Canada’s largest pharmacy chains and drug stores. Mr. Pirooz is also the CEO and a director of Genix Pharmaceuticals Corporation, a company listed for trading on the TSXV.

Dr. Sazzad Hossain, PhD

Chief Scientific Officer

He is the former Chief Scientific Officer of InMed Pharmaceuticals Inc., a leading public Canadian bio-pharmaceutical company. Previously he worked as Senior Scientist at Biotechnology Research Institute of National Research Council Canada. Working with the Canadian government he helped establish the pharmacology laboratory to evaluate safety and efficacy of cannabinoid-based and other drugs under development for cancer, cardiovascular and ocular diseases.

Jacob Moshinsky

Chief Operating Officer

Jacob is the CEO & founder of MoviWear a GPS, fall down detection & remote vital-sign monitoring platform, alerting caregivers of real-time emergencies. Jacob is a communications and technology expert with over 15 years’ experience in the field. the NurtureWatch health monitoring Smartwatch and MoviWearMED remote vital sign monitoring platform Prior to MoviWear, Jacob worked in both the Canadian telecom and the CPG industry. He led the Product Development and Business Strategy team at TELUS for the Small Business Portfolio. Jacob also worked in various product and service management roles within Rogers Communications where he launched and managed wireless and wireline products.

Antonio Baldassarre

CEO, President and Director

Mr. Baldassarre has held senior management and director positions of new business start-ups and established multinational organizations with over 30 years of experience in the Security, Information Technology and Communications industries. With leadership skills in management of international operations, shareholder exit strategies, and overall business development, he has utilized a wide range of strategic programs to maximize organic growth into specific industry segments through OEM, alliances, and direct multi-level distribution channels. Mr. Baldassarre is able to plan, organize and direct all aspects of a Corporation from Operations, P&L oversight, product distribution, Product promotions, sales and development activities and initiatives utilizing my extensive marketing/sales senior management experience with developed abilities in team leadership and program/campaign development. Directly involved in the growth, branding and ultimately optimizing market share, product awareness, revenues, profitability and shareholder value. Mr. Baldassare is also the President of LRG Security Canada Inc. and LRG Security Europe.

Franco Staino

Chairman of the Board of Directors

Mr. Franco Staino is the Developer of the Italian National anti-counterfeiting Program for Pharmaceuticals developed in conjunction with the Ministry of Health as well as the National Certification Program for all unsold Prescription Drugs in Partnership with Pharmindustria (National association of all Pharmaceutical Manufactures) through ASSINDE.

Through one of his Companies, Carlucci are responsible for the control, labelling and collection of all pharmaceutical prescription drugs in Italy, under the PHG umbrella Franco opened first a UK division, now has also expanded into 4 African countries. Over the Years Franco has been a Board Member and Contributor on various International Committees, including the United Nations.